Gilead's Latest Deal Shows Big Pharma's Appetite For Oral Peptides. Which Stocks Are Worth Watching?
Its $1.275 billion upfront commitment to a Phase 1 program puts the spotlight on oral peptide developers, including Entera as it approaches Phase 3 in
DO
By Daniel Okafor · Regulatory Correspondent
Oct 26 02:04 ETSource: Menafn
From the source
Read at menafn.comGilead's Latest Deal Shows Big Pharma's Appetite For Oral Peptides. Which Stocks Are Worth Watching?
Its $1.275 billion upfront commitment to a Phase 1 program puts the spotlight on oral peptide developers, including Entera as it approaches Phase 3 in osteoporosis.
